FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803499191> ?p ?o ?g. }

• W2803499191 endingPage "759.e5" @default.
• W2803499191 startingPage "752" @default.
• W2803499191 abstract "Background & AimsDominant strictures occur in approximately 50% of patients with primary sclerosing cholangitis (PSC). Short-term stents have been reported to produce longer resolution of dominant strictures than single-balloon dilatation. We performed a prospective study to compare the efficacy and safety of balloon dilatation vs short-term stents in patients with non–end-stage PSC.MethodsWe performed an open-label trial of patients with PSC undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) at 9 tertiary-care centers in Europe, from July 2011 through April 2016. Patients found to have a dominant stricture during ERCP were randomly assigned to groups that underwent balloon dilatation (n = 31) or stent placement for a maximum of 2 weeks (n = 34); patients were followed for 24 months. The primary outcome was the cumulative recurrence-free patency of the primary dominant strictures.ResultsStudy recruitment was terminated after a planned interim analysis because of futility and differences in treatment-related serious adverse events (SAEs) between groups. The cumulative recurrence-free rate did not differ significantly between groups (0.34 for the stent group and 0.30 for the balloon dilatation group at 24 months; P = 1.0). Most patients in both groups had reductions in symptoms at 3 months after the procedure. There were 17 treatment-related SAEs: post-ERCP pancreatitis in 9 patients and bacterial cholangitis in 4 patients. SAEs occurred in 15 patients in the stent group (45%) and in only 2 patients in the balloon dilatation group (6.7%) (odds ratio, 11.7; 95% confidence interval, 2.4–57.2; P = .001).ConclusionsIn a multicenter randomized trial of patients with PSC and a dominant stricture, short-term stents were not superior to balloon dilatation and were associated with a significantly higher occurrence of treatment-related SAEs. Balloon dilatation should be the initial treatment of choice for dominant strictures in patients with PSC. This may be particularly relevant to patients with an intact papilla. ClinicalTrials.gov no. NCT01398917. Dominant strictures occur in approximately 50% of patients with primary sclerosing cholangitis (PSC). Short-term stents have been reported to produce longer resolution of dominant strictures than single-balloon dilatation. We performed a prospective study to compare the efficacy and safety of balloon dilatation vs short-term stents in patients with non–end-stage PSC. We performed an open-label trial of patients with PSC undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) at 9 tertiary-care centers in Europe, from July 2011 through April 2016. Patients found to have a dominant stricture during ERCP were randomly assigned to groups that underwent balloon dilatation (n = 31) or stent placement for a maximum of 2 weeks (n = 34); patients were followed for 24 months. The primary outcome was the cumulative recurrence-free patency of the primary dominant strictures. Study recruitment was terminated after a planned interim analysis because of futility and differences in treatment-related serious adverse events (SAEs) between groups. The cumulative recurrence-free rate did not differ significantly between groups (0.34 for the stent group and 0.30 for the balloon dilatation group at 24 months; P = 1.0). Most patients in both groups had reductions in symptoms at 3 months after the procedure. There were 17 treatment-related SAEs: post-ERCP pancreatitis in 9 patients and bacterial cholangitis in 4 patients. SAEs occurred in 15 patients in the stent group (45%) and in only 2 patients in the balloon dilatation group (6.7%) (odds ratio, 11.7; 95% confidence interval, 2.4–57.2; P = .001). In a multicenter randomized trial of patients with PSC and a dominant stricture, short-term stents were not superior to balloon dilatation and were associated with a significantly higher occurrence of treatment-related SAEs. Balloon dilatation should be the initial treatment of choice for dominant strictures in patients with PSC. This may be particularly relevant to patients with an intact papilla. ClinicalTrials.gov no. NCT01398917." @default.
• W2803499191 created "2018-06-01" @default.
• W2803499191 creator A5000830051 @default.
• W2803499191 creator A5004457925 @default.
• W2803499191 creator A5009822661 @default.
• W2803499191 creator A5013603537 @default.
• W2803499191 creator A5014440683 @default.
• W2803499191 creator A5018212784 @default.
• W2803499191 creator A5018789818 @default.
• W2803499191 creator A5023726045 @default.
• W2803499191 creator A5025092611 @default.
• W2803499191 creator A5036810251 @default.
• W2803499191 creator A5052219587 @default.
• W2803499191 creator A5053434760 @default.
• W2803499191 creator A5061062761 @default.
• W2803499191 creator A5065139294 @default.
• W2803499191 creator A5066537961 @default.
• W2803499191 creator A5070759942 @default.
• W2803499191 creator A5077811550 @default.
• W2803499191 creator A5078832883 @default.
• W2803499191 creator A5082755452 @default.
• W2803499191 creator A5086399423 @default.
• W2803499191 creator A5089812717 @default.
• W2803499191 date "2018-09-01" @default.
• W2803499191 modified "2023-10-17" @default.
• W2803499191 title "No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis" @default.
• W2803499191 cites W1479884833 @default.
• W2803499191 cites W1968970101 @default.
• W2803499191 cites W1975646098 @default.
• W2803499191 cites W1992420413 @default.
• W2803499191 cites W1994344135 @default.
• W2803499191 cites W2015627863 @default.
• W2803499191 cites W2024422356 @default.
• W2803499191 cites W2029790242 @default.
• W2803499191 cites W2041538832 @default.
• W2803499191 cites W2043813971 @default.
• W2803499191 cites W2069124048 @default.
• W2803499191 cites W2071602569 @default.
• W2803499191 cites W2085171426 @default.
• W2803499191 cites W2143030437 @default.
• W2803499191 cites W2607081164 @default.
• W2803499191 cites W2786456523 @default.
• W2803499191 cites W3144026819 @default.
• W2803499191 cites W4231196144 @default.
• W2803499191 doi "https://doi.org/10.1053/j.gastro.2018.05.034" @default.
• W2803499191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29803836" @default.
• W2803499191 hasPublicationYear "2018" @default.
• W2803499191 type Work @default.
• W2803499191 sameAs 2803499191 @default.
• W2803499191 citedByCount "62" @default.
• W2803499191 countsByYear W28034991912018 @default.
• W2803499191 countsByYear W28034991912019 @default.
• W2803499191 countsByYear W28034991912020 @default.
• W2803499191 countsByYear W28034991912021 @default.
• W2803499191 countsByYear W28034991912022 @default.
• W2803499191 countsByYear W28034991912023 @default.
• W2803499191 crossrefType "journal-article" @default.
• W2803499191 hasAuthorship W2803499191A5000830051 @default.
• W2803499191 hasAuthorship W2803499191A5004457925 @default.
• W2803499191 hasAuthorship W2803499191A5009822661 @default.
• W2803499191 hasAuthorship W2803499191A5013603537 @default.
• W2803499191 hasAuthorship W2803499191A5014440683 @default.
• W2803499191 hasAuthorship W2803499191A5018212784 @default.
• W2803499191 hasAuthorship W2803499191A5018789818 @default.
• W2803499191 hasAuthorship W2803499191A5023726045 @default.
• W2803499191 hasAuthorship W2803499191A5025092611 @default.
• W2803499191 hasAuthorship W2803499191A5036810251 @default.
• W2803499191 hasAuthorship W2803499191A5052219587 @default.
• W2803499191 hasAuthorship W2803499191A5053434760 @default.
• W2803499191 hasAuthorship W2803499191A5061062761 @default.
• W2803499191 hasAuthorship W2803499191A5065139294 @default.
• W2803499191 hasAuthorship W2803499191A5066537961 @default.
• W2803499191 hasAuthorship W2803499191A5070759942 @default.
• W2803499191 hasAuthorship W2803499191A5077811550 @default.
• W2803499191 hasAuthorship W2803499191A5078832883 @default.
• W2803499191 hasAuthorship W2803499191A5082755452 @default.
• W2803499191 hasAuthorship W2803499191A5086399423 @default.
• W2803499191 hasAuthorship W2803499191A5089812717 @default.
• W2803499191 hasBestOaLocation W28034991912 @default.
• W2803499191 hasConcept C126322002 @default.
• W2803499191 hasConcept C126838900 @default.
• W2803499191 hasConcept C139059822 @default.
• W2803499191 hasConcept C141071460 @default.
• W2803499191 hasConcept C156957248 @default.
• W2803499191 hasConcept C168563851 @default.
• W2803499191 hasConcept C197934379 @default.
• W2803499191 hasConcept C203092338 @default.
• W2803499191 hasConcept C2775967933 @default.
• W2803499191 hasConcept C2778444009 @default.
• W2803499191 hasConcept C2778583881 @default.
• W2803499191 hasConcept C2779134260 @default.
• W2803499191 hasConcept C2780615123 @default.
• W2803499191 hasConcept C3019365145 @default.
• W2803499191 hasConcept C44249647 @default.
• W2803499191 hasConcept C71924100 @default.
• W2803499191 hasConceptScore W2803499191C126322002 @default.
• W2803499191 hasConceptScore W2803499191C126838900 @default.
• W2803499191 hasConceptScore W2803499191C139059822 @default.

• next